Tolvaptan in ADPKD Beyond Trials: Tolerability, Monitoring, and Real-World Outcomes

Abstract excerpt

<title>Abstract</title> <p>Background Tolvaptan is the only approved disease-modifying therapy for autosomal dominant polycystic kidney disease (ADPKD). Real-world evidence on its safety and tolerability remains limited, particularly in Central and Eastern Europe, where access to therapy has recently expanded through national reimbursement programs. Methods This study objective was to evaluate treatment tolerab...

Topics

Open a Topic to create a Post that cites this publication.

• Drug Development
• Drugs, Investigational
• Genetic Therapy
• Glomerular Filtration Rate
• MicroRNAs
• Mutation
• Polycystic Kidney, Autosomal Dominant
• TRPP Cation Channels

Identifiers and source

Literature Corpus work

1a022907-f133-5a86-9551-81a3937d62dd

DOI

10.21203/rs.3.rs-8216058/v1